| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $82M |
Buys | $9,993,082 | 2 | 7 |
Sells | $38,364,689 | 25 | 93 |
| Mulligan Seamus | director | 2 | $9.99M | 0 | $0 | $9.99M |
| McSharry Heather Ann | director | 0 | $0 | 1 | $607,127 | $-607,127 |
| RIEDEL NORBERT G | director | 0 | $0 | 1 | $655,680 | $-655,680 |
| Winningham Rick E | director | 0 | $0 | 1 | $994,728 | $-994,728 |
| Iannone Robert | EVP, Global Head of R&D & CMO | 0 | $0 | 1 | $1.2M | $-1.2M |
| Henderson Mary Elizabeth | SVP, Technical Operations | 0 | $0 | 2 | $1.42M | $-1.42M |
| Carr Patricia | SVP, Chief Accounting Officer | 0 | $0 | 5 | $2.46M | $-2.46M |
| Patil Neena M | EVP & Chief Legal Officer | 0 | $0 | 1 | $10.65M | $-10.65M |
| COZADD BRUCE C | Chairman & CEO | 0 | $0 | 13 | $20.38M | $-20.38M |
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Over the last 12 months, insiders at Jazz Pharmaceuticals plc have bought $9.99M and sold $38.36M worth of Jazz Pharmaceuticals plc stock.
On average, over the past 5 years, insiders at Jazz Pharmaceuticals plc have bought $5.71M and sold $15.75M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Mulligan Seamus (director) — $9.99M.
The last purchase of 1,621 shares for transaction amount of $166,962 was made by Mulligan Seamus (director) on 2025‑05‑12.
| 2026-03-09 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 1,287 0.0021% | $182.94 | $235,444 | -1.64% | |
| 2026-03-03 | Sale | COZADD BRUCE C | director | 6,000 0.0095% | $186.44 | $1.12M | -0.93% | |
| 2026-02-27 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 1,117 0.0018% | $190.91 | $213,243 | -2.32% | |
| 2026-02-27 | Sale | RIEDEL NORBERT G | director | 3,415 0.0057% | $192.00 | $655,680 | -2.32% | |
| 2026-02-26 | Sale | Patil Neena M | EVP & Chief Legal Officer | 55,600 0.0928% | $191.56 | $10.65M | -3.85% | |
| 2026-02-26 | Sale | Henderson Mary Elizabeth | SVP, Technical Operations | 5,343 0.009% | $194.49 | $1.04M | -3.85% | |
| 2026-02-26 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 1,253 0.0021% | $194.11 | $243,222 | -3.85% | |
| 2025-12-09 | Sale | Henderson Mary Elizabeth | SVP, Technical Operations | 2,238 0.0038% | $169.51 | $379,366 | +4.39% | |
| 2025-12-05 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 4,660 0.0077% | $171.20 | $797,783 | -0.25% | |
| 2025-11-26 | Sale | COZADD BRUCE C | director | 77,500 0.1282% | $177.81 | $13.78M | -4.33% | |
| 2025-11-20 | Sale | McSharry Heather Ann | director | 3,415 0.0057% | $177.78 | $607,127 | -3.61% | |
| 2025-11-18 | Sale | COZADD BRUCE C | director | 18,000 0.0297% | $181.09 | $3.26M | -6.14% | |
| 2025-11-18 | Sale | Winningham Rick E | director | 5,500 0.0091% | $180.86 | $994,728 | -6.14% | |
| 2025-11-18 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 5,319 0.0088% | $182.06 | $968,402 | -6.14% | |
| 2025-11-17 | Sale | Iannone Robert | EVP, Global Head of R&D & CMO | 7,159 0.0117% | $168.26 | $1.2M | -0.36% | |
| 2025-10-03 | Sale | COZADD BRUCE C | director | 3,500 0.0061% | $140.00 | $490,000 | +19.76% | |
| 2025-10-01 | Sale | COZADD BRUCE C | director | 2,000 0.0033% | $131.78 | $263,560 | +21.98% | |
| 2025-09-02 | Sale | COZADD BRUCE C | director | 6,000 0.0098% | $128.62 | $771,690 | +27.57% | |
| 2025-08-01 | Sale | COZADD BRUCE C | Chairman & CEO | 1,000 0.0016% | $113.21 | $113,210 | +40.53% | |
| 2025-07-01 | Sale | COZADD BRUCE C | Chairman & CEO | 1,000 0.0016% | $107.63 | $107,630 | +26.25% |
| COZADD BRUCE C | director | 405796 0.6592% | $72.45M | 1 | 118 | +194.39% |
| Mulligan Seamus | director | 101621 0.1651% | $18.14M | 5 | 18 | +20.05% |
| Iannone Robert | EVP, Global Head of R&D & CMO | 72628 0.118% | $12.97M | 0 | 4 | |
| Patil Neena M | EVP & Chief Legal Officer | 56862 0.0924% | $10.15M | 0 | 10 | |
| Henderson Mary Elizabeth | SVP, Technical Operations | 28728 0.0467% | $5.13M | 0 | 3 | |
| McSharry Heather Ann | director | 20449 0.0332% | $3.65M | 0 | 11 | |
| Winningham Rick E | director | 8893 0.0144% | $1.59M | 0 | 15 | |
| RIEDEL NORBERT G | director | 7024 0.0114% | $1.25M | 0 | 13 | |
| Carr Patricia | SVP, Chief Accounting Officer | 6512 0.0106% | $1.16M | 0 | 35 | |
| MICHELSON MICHAEL W | director | 9906501 16.0924% | $1.77B | 1 | 0 | <0.0001% |
| RAETHER PAUL E | 9906501 16.0924% | $1.77B | 1 | 0 | <0.0001% | |
| KKR JP LLC | 9906501 16.0924% | $1.77B | 1 | 0 | <0.0001% | |
| BRIDGER MANAGEMENT LLC | 10 percent owner | 2667050 4.3324% | $476.2M | 9 | 0 | <0.0001% |
| COLELLA SAMUEL D | director | 1488676 2.4182% | $265.8M | 1 | 0 | <0.0001% |
| TANANBAUM JAMES B | director | 1403129 2.2793% | $250.53M | 1 | 0 | <0.0001% |
| Saks Samuel R | Chief Executive Officer | 347001 0.5637% | $61.96M | 3 | 0 | <0.0001% |
| MYERS ROBERT M | President | 152206 0.2472% | $27.18M | 1 | 3 | +175.25% |
| FALBERG KATHRYN E | EVP and CFO | 124721 0.2026% | $22.27M | 3 | 9 | +139.43% |
| SEBULSKY ALAN | director | 54355 0.0883% | $9.71M | 2 | 1 | +8.7% |
| Wissel Janne LT | SVP, Chief Regulatory Officer | 47221 0.0767% | $8.43M | 0 | 3 | |
| Cox Russell J. | EVP & COO | 47095 0.0765% | $8.41M | 0 | 13 | |
| Hooper Suzanne Sawochka | EVP & General Counsel | 39738 0.0646% | $7.1M | 0 | 26 | |
| Young Matthew P. | EVP & CFO | 36200 0.0588% | $6.46M | 0 | 17 | |
| GALA RENEE D | EVP & Chief Financial Officer | 35978 0.0584% | $6.42M | 0 | 2 | |
| Tobias Jeffrey K | EVP, R&D & CMO | 35063 0.057% | $6.26M | 0 | 17 | |
| Gamble Carol A | SVP and General Counsel | 32213 0.0523% | $5.75M | 0 | 5 | |
| Keegan Fintan | EVP, Technical Operations | 31750 0.0516% | $5.67M | 0 | 10 | |
| Sablich Kim | EVP, GM of U.S., Commercial Ma | 30560 0.0496% | $5.46M | 0 | 3 | |
| Johnson Philip L | EVP & Chief Financial Officer | 27932 0.0454% | $4.99M | 1 | 0 | <0.0001% |
| CRESSEY BRYAN C | director | 27631 0.0449% | $4.93M | 1 | 2 | <0.0001% |
| O'Keefe Kenneth W | director | 24723 0.0402% | $4.41M | 3 | 15 | <0.0001% |
| MILLER MICHAEL PATRICK | EVP, US Commercial | 22118 0.0359% | $3.95M | 0 | 40 | |
| Larkin Finbar | SVP, Technical Operations | 21779 0.0354% | $3.89M | 0 | 13 | |
| ENRIGHT PATRICK G | director | 20946 0.034% | $3.74M | 3 | 47 | +41.06% |
| McGill Iain | SVP, Europe & Rest of World | 20383 0.0331% | $3.64M | 0 | 4 | |
| MOMTAZEE JAMES C | director | 17315 0.0281% | $3.09M | 0 | 1 | |
| Treacy Paul | SVP, Technical Operations | 16418 0.0267% | $2.93M | 0 | 11 | |
| Gray Peter | director | 16068 0.0261% | $2.87M | 0 | 9 | |
| WILSON KAREN J | SVP, Finance & PAO | 15757 0.0256% | $2.81M | 0 | 18 | |
| Sohn Catherine A. | director | 14868 0.0242% | $2.65M | 0 | 13 | |
| Tovey Christopher J. | EVP, COO & Managing Director E | 14663 0.0238% | $2.62M | 0 | 1 | |
| Smith Karen L. | Global Head of R&D and CMO | 14182 0.023% | $2.53M | 3 | 0 | <0.0001% |
| ORiordan Anne | director | 12551 0.0204% | $2.24M | 0 | 3 | |
| Colligan Joan | Principal Accounting Officer | 11384 0.0185% | $2.03M | 0 | 1 | |
| Pearce Samantha | SVP, Head of Europe & Internat | 11309 0.0184% | $2.02M | 0 | 9 | |
| BERNS PAUL L | director | 8290 0.0135% | $1.48M | 0 | 11 | |
| Schnee Elmar | director | 8270 0.0134% | $1.48M | 0 | 4 | |
| KKR JP III LLC | 10 percent owner | 7888 0.0128% | $1.41M | 0 | 2 | |
| KKR Fund Holdings L.P. | 10 percent owner | 7888 0.0128% | $1.41M | 0 | 2 | |
| Cook Jennifer E. | director | 6888 0.0112% | $1.23M | 0 | 5 | |
| Smith Mark Douglas | director | 6888 0.0112% | $1.23M | 0 | 5 | |
| KKR FINANCIAL HOLDINGS III, LLC | 0 0% | $0 | 0 | 2 | ||
| KKR Group Holdings L.P. | 10 percent owner | 0 0% | $0 | 0 | 2 |
$961,890,236 | 276 | 22.46% | $18.42B | |
$211,610,344 | 91 | 38.45% | $10.1B | |
$2,765,836 | 72 | 20.00% | $11.25B | |
$108,876,545 | 67 | 72.81% | $7.51B | |
Jazz Pharmaceuticals plc (JAZZ) | $88,307,390 | 38 | -1.70% | $10.99B |
$19,233,721 | 36 | 70.14% | $11.06B | |
$1,801,511 | 23 | 18.58% | $7.71B | |
$415,090,639 | 19 | -14.04% | $13.46B | |
$11,859,102 | 17 | 18.62% | $7.4B | |
$143,065,458 | 17 | 8.01% | $18.8B | |
$1,279,017 | 16 | 51.12% | $7.98B | |
$152,272,932 | 16 | -10.78% | $19.56B | |
$627,701,115 | 15 | 145.68% | $12B | |
$284,820 | 10 | 45.67% | $11.76B | |
$11,898,979 | 10 | 54.58% | $7.23B | |
$948,235 | 8 | 15.56% | $7.96B | |
$55,713,031 | 8 | -0.36% | $8.63B | |
$41,376,000 | 4 | -12.07% | $7.86B | |
$40,276,273 | 4 | 34.57% | $20.08B |
| Increased Positions | 316 | +55.24% | 9M | +14.8% |
| Decreased Positions | 248 | -43.36% | 8M | -12.85% |
| New Positions | 129 | New | 1M | New |
| Sold Out Positions | 56 | Sold Out | 530,752 | Sold Out |
| Total Postitions | 640 | +11.89% | 62M | +1.94% |
| Vanguard Group Inc | $1.02M | 9.68% | 5.91M | -183,927 | -3.02% | 2025-09-30 |
| Blackrock, Inc. | $962,595.00 | 9.11% | 5.56M | -240,404 | -4.14% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $491,166.00 | 4.65% | 2.84M | +298,815 | +11.77% | 2025-09-30 |
| Capital World Investors | $442,375.00 | 4.19% | 2.55M | +10,345 | +0.41% | 2025-09-30 |
| Lsv Asset Management | $434,928.00 | 4.12% | 2.51M | -41,884 | -1.64% | 2025-09-30 |
| State Street Corp | $323,424.00 | 3.06% | 1.87M | -67,499 | -3.49% | 2025-09-30 |
| Jpmorgan Chase & Co | $323,299.00 | 3.06% | 1.87M | +145,865 | +8.47% | 2025-09-30 |
| Ameriprise Financial Inc | $319,887.00 | 3.03% | 1.85M | -19,944 | -1.07% | 2025-09-30 |
| Ecor1 Capital, Llc | $295,475.00 | 2.8% | 1.71M | 0 | 0% | 2025-09-30 |
| Fuller & Thaler Asset Management, Inc. | $281,565.00 | 2.67% | 1.63M | -2,823 | -0.17% | 2025-09-30 |